이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

새로 진단된 고위험 신경모세포종 아동 치료를 위한 화학요법, 수술 및 줄기세포 이식을 병용한 디누툭시맙

2026년 10월 29일 업데이트: National Cancer Institute (NCI)

새로 진단된 고위험 신경모세포종 아동을 위한 집중 복합요법에 디누툭시맙을 추가한 제3상 연구

This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.

연구 개요

상태

모병

정황

상세 설명

PRIMARY OBJECTIVE:

I. To determine if the event-free survival (EFS) of patients with newly diagnosed high-risk neuroblastoma assigned to early chemoimmunotherapy during Induction differs from that of patients who are not assigned to treatment that includes early chemoimmunotherapy.

SECONDARY OBJECTIVES:

I. To determine if early chemoimmunotherapy during Induction therapy improves end of Induction (EOI) response rates and overall survival (OS) for patients with newly diagnosed high-risk neuroblastoma.

II. To determine response rates, EFS, and OS following an Extended Induction regimen with chemoimmunotherapy in patients with progressive disease or a poor response to Induction therapy.

III. To compare the toxicities experienced by patients treated with chemoimmunotherapy during Induction versus those experienced by patients treated with standard Induction and to describe toxicities experienced during Extended Induction.

IV. To determine GD2 expression on tumor tissue and tumor cells in bone marrow and assess for associations with response and outcome.

EXPLORATORY OBJECTIVES:

I. To describe the association between tumor and host factors and outcomes in patients receiving protocol therapy.

II. To evaluate circulating biomarkers and markers of minimal residual disease at baseline and during therapy, and assess for associations with response and outcome.

III. To compare patterns of failure between patients treated with and without dinutuximab during induction.

IV. To determine the effect of telomere maintenance mechanisms on end of Induction response rates, EFS, and OS.

V. To explore the impact of high-risk neuroblastoma (HRNBL) and its therapy, including the addition of dinutuximab to Induction chemotherapy, on functional and quality of life outcomes in patients with HRNBL, as measured by caregiver (parent/legal guardian) and patient questionnaires.

VI. To describe the adequacy of diagnostic biopsy specimens, including those obtained by percutaneous core needle biopsy.

VII. To explore the associations between family-reported adverse social determinants of health and both clinical outcomes and biology.

VIII. To develop and validate deep learning predictors of Induction response based on diagnostic MIBG scans. (Imaging Objective) IX. To compare institutional versus central determination of overall response, individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease), and poor end of induction response (PEIR) and good end of induction response (GEIR) determination. (Imaging Objective) X. To describe late toxicities (including impaired organ function, neuropsychiatric toxicity, and incidence of secondary malignancy) in patients treated with dinutuximab during Induction or Extended Induction to late toxicities in patients who have not received dinutuximab during these phases of therapy.

XI. To evaluate whether reduced dose radiotherapy to the primary site clinical target volume (CTV) in patients with complete response of the primary site at EOI results in comparable local control relative to historical cohorts.

XII. To compare post-transplant complications between treatment arms, and assess for associations with outcome.

XIII. To assess for associations between EOI response (including good end of Induction response [GEIR] and poor end of Induction response [PEIR]) and individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease) with outcome (EFS and OS).

XIV. To describe and compare the changes in image-defined risk factors (IDRFs) between patients treated with and without dinutuximab during Induction and associate with surgical outcomes and local failure rates following primary tumor resection.

XV. To bank serial samples of blood, bone marrow, and tumor tissue for future research.

OUTLINE: Patients receive Induction cycle 1 and are then randomized to 1 of 2 treatment arms.

INDUCTION CYCLE 1: Patients receive cyclophosphamide intravenously (IV) over 30 minutes and topotecan IV over 30 minutes on days 1-5 in the absence of unacceptable toxicity.

ARM A:

INDUCTION CYCLES 2-5: Patients receive cyclophosphamide IV over 30 minutes and topotecan IV over 30 minutes on days 1-5 of cycle 2 in the absence of unacceptable toxicity. Patients then undergo stem cell harvest via apheresis. Patients then receive cisplatin IV over 4 hours and etoposide IV over 2 hours on days 1-3 of cycles 3 and 5, and vincristine IV on day 1, doxorubicin IV over 15 minutes, and cyclophosphamide IV over 1 hour on days 1-2 of cycle 4 in the absence of unacceptable toxicity. Patients undergo primary tumor resection after Induction cycle 4 or 5. Following Induction cycle 5, patients undergo testing to determine response to Induction therapy. Patients with a good tumor response proceed to Consolidation, while patients with a poor tumor response proceed to Extended Induction.

EXTENDED INDUCTION: Patients with a poor tumor response or progression during Induction receive temozolomide orally (PO), via nasogastric tube (NG), or via gastric tube (G-tube) on days 1-5, irinotecan IV over 90 minutes on days 1-5, and dinutuximab IV over 10 hours. Treatment repeats every 21 days for up to a maximum of 6 cycles in the absence of disease progression or unacceptable toxicity. If at any time during Extended Induction testing shows a good tumor response, patients proceed to Consolidation. If after 6 cycles of Extended Induction or if at any time progression is noted, patients are removed from the study.

CONSOLIDATION: Patients undergo two autologous hematopoietic stem cell transplantations (HSCTs) during Consolidation. Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 1 hour on days -5 to -2 during HSCT 1. Patients then receive stem cell infusion IV on day 0. Between 6 and 10 weeks after stem cell infusion, patients receive melphalan IV over 30 minutes on days -7 to -5, etoposide IV over 24 hours on days -7 to -4, and carboplatin over 24 hours on days -7 to -4 during HSCT 2. Patients receive stem cell infusion IV on day 0. Between day +42 and day +80 after HSCT 2. Patients receive radiation daily for 12 treatments in the absence of disease progression or unacceptable toxicity.

POST CONSOLIDATION: Patients receive dinutuximab IV over 10 hours on days 4-7 and isotretinoin PO twice daily (BID) on days 11-24 of cycles 1-5. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive isotretinoin PO BID on days 15-28 for 1 additional cycle, cycle 6.

Patients undergo blood and urine sample collection, echocardiogram (ECHO) or multigated acquisition scan (MUGA), bone marrow aspiration and/or biopsy, computed tomography (CT) scan, magnetic resonance imaging (MRI), iodine-123 meta-iodobenzylguanidine (I-MIBG) scan and possible fluorodeoxyglucose position emission tomography (FDG-PET) scan throughout the study.

ARM B:

INDUCTION CYCLES 2-5: Patients receive cyclophosphamide IV over 30 minutes, topotecan IV over 30 minutes on days 1-5, and dinutuximab IV over 10 hours on days 2-5 of cycle 2 in the absence of unacceptable toxicity. Patients then undergo stem cell harvest via apheresis. Patients receive cisplatin IV over 4 hours and etoposide IV over 2 hours on days 1-3 and dinutuximab IV over 10 hours on days 2-5 of cycles 3 and 5, and vincristine IV on day 1, doxorubicin IV over 15 minutes, and cyclophosphamide IV over 1 hour on days 1-2, and dinutuximab IV over 10 hours on days 2-5 of cycle 4 in the absence of unacceptable toxicity. Patients undergo primary tumor resection after Induction cycle 4 or 5. Following Induction cycle 5, patients undergo testing to determine response to Induction therapy. Patients with a good tumor response proceed to Consolidation, while patients with a poor tumor response proceed to Extended Induction.

EXTENDED INDUCTION: Patients with a poor tumor response or progression during Induction receive temozolomide PO, via NG tube, or via G-tube on days 1-5, irinotecan IV over 90 minutes on days 1-5, and dinutuximab IV over 10 hours. Treatment repeats every 21 days for up to a maximum of 6 cycles in the absence of disease progression or unacceptable toxicity. If at any time during Extended Induction testing shows a good tumor response, patients proceed to Consolidation. If after 6 cycles of Extended Induction or if at any time progression is noted, patients are removed from the study.

CONSOLIDATION: Patients undergo two autologous HSCTs during Consolidation. Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 1 hour on days -5 to -2 during HSCT 1. Patients then receive stem cell infusion IV on day 0. Between 6 and 10 weeks after stem cell infusion patients receive melphalan IV over 30 minutes on days -7 to -5, etoposide IV over 24 hours on days -7 to -4, and carboplatin over 24 hours on days -7 to -4 during HSCT 2. Patients receive stem cell infusion IV on day 0. Between day +42 and day +80 after HSCT 2, patients receive radiation daily for 12 treatments in the absence of disease progression or unacceptable toxicity.

POST CONSOLIDATION: Patients receive dinutuximab IV over 10 hours on days 4-7 and isotretinoin PO BID on days 11-24 of cycles 1-5. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive isotretinoin PO BID on days 15-28 for 1 additional cycle, cycle 6.

Patients undergo blood and urine sample collection, ECHO or MUGA, bone marrow aspiration and/or biopsy, CT scan, MRI, I-MIBG scan and possible FDG-PET scan throughout the study.

After completion of study treatment, patients are followed up at 3, 6, 9,12, 15, 18, 24, 30, 36, 42, 48, 54, and 60 months and then periodically for up to 10 years from enrollment.

연구 유형

중재적

등록 (추정된)

478

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Auckland
      • Grafton, Auckland, 뉴질랜드, 1145
        • 모병
        • Starship Children's Hospital
        • 수석 연구원:
          • Andrew C. Wood
        • 연락하다:
          • Site Public Contact
          • 전화번호: 0800 728 436
    • Alabama
      • Birmingham, Alabama, 미국, 35233
        • 모병
        • Children's Hospital of Alabama
        • 연락하다:
        • 수석 연구원:
          • Elizabeth D. Alva
      • Mobile, Alabama, 미국, 36604
        • 모병
        • USA Health Strada Patient Care Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 800-388-8721
        • 수석 연구원:
          • Hamayun Imran
    • Arizona
      • Mesa, Arizona, 미국, 85202
        • 모병
        • Banner Children's at Desert
        • 연락하다:
          • Site Public Contact
          • 전화번호: 480-412-3100
        • 수석 연구원:
          • Joseph C. Torkildson
      • Phoenix, Arizona, 미국, 85016
        • 모병
        • Phoenix Childrens Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 602-546-0920
        • 수석 연구원:
          • Alok K. Kothari
      • Tucson, Arizona, 미국, 85719
        • 모병
        • Banner University Medical Center - Tucson
        • 연락하다:
        • 수석 연구원:
          • Monica M. Davini
    • Arkansas
      • Little Rock, Arkansas, 미국, 72202-3591
        • 모병
        • Arkansas Children's Hospital
        • 수석 연구원:
          • Michael W. Bishop
        • 연락하다:
          • Site Public Contact
          • 전화번호: 501-364-7373
    • California
      • Downey, California, 미국, 90242
        • 모병
        • Kaiser Permanente Downey Medical Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 626-564-3455
        • 수석 연구원:
          • Robert M. Cooper
      • Duarte, California, 미국, 91010
        • 모병
        • City of Hope Comprehensive Cancer Center
        • 연락하다:
        • 수석 연구원:
          • Hung C. Tran
      • Loma Linda, California, 미국, 92354
        • 모병
        • Loma Linda University Medical Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 909-558-4050
        • 수석 연구원:
          • Albert Kheradpour
      • Long Beach, California, 미국, 90806
        • 모병
        • Miller Children's and Women's Hospital Long Beach
        • 연락하다:
          • Site Public Contact
          • 전화번호: 562-933-5600
        • 수석 연구원:
          • Jacqueline N. Casillas
      • Los Angeles, California, 미국, 90027
        • 모병
        • Children's Hospital Los Angeles
        • 연락하다:
          • Site Public Contact
          • 전화번호: 323-361-4110
        • 수석 연구원:
          • Araz Marachelian
      • Los Angeles, California, 미국, 90048
        • 모병
        • Cedars-Sinai Medical Center
        • 수석 연구원:
          • Fataneh (Fae) Majlessipour
        • 연락하다:
      • Los Angeles, California, 미국, 90095
        • 모병
        • Mattel Children's Hospital UCLA
        • 연락하다:
          • Site Public Contact
          • 전화번호: 310-825-6708
        • 수석 연구원:
          • Satiro N. De Oliveira
      • Madera, California, 미국, 93636
        • 모병
        • Valley Children's Hospital
        • 연락하다:
        • 수석 연구원:
          • Ruetima Titapiwatanakun
      • Oakland, California, 미국, 94611
        • 모병
        • Kaiser Permanente-Oakland
        • 연락하다:
          • Site Public Contact
          • 전화번호: 877-642-4691
          • 이메일: Kpoct@kp.org
        • 수석 연구원:
          • Aarati V. Rao
      • Oakland, California, 미국, 94609
        • 모병
        • UCSF Benioff Children's Hospital Oakland
        • 수석 연구원:
          • Jennifer G. Michlitsch
        • 연락하다:
      • Orange, California, 미국, 92868
        • 모병
        • Children's Hospital of Orange County
        • 연락하다:
        • 수석 연구원:
          • Elyssa M. Rubin
      • Palo Alto, California, 미국, 94304
        • 모병
        • Lucile Packard Children's Hospital Stanford University
        • 연락하다:
        • 수석 연구원:
          • Jay Michael S. Balagtas
      • Sacramento, California, 미국, 95817
        • 모병
        • University of California Davis Comprehensive Cancer Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 916-734-3089
        • 수석 연구원:
          • Marcio H. Malogolowkin
      • Sacramento, California, 미국, 95816
      • San Diego, California, 미국, 92123
        • 모병
        • Rady Children's Hospital - San Diego
        • 연락하다:
          • Site Public Contact
          • 전화번호: 858-966-5934
        • 수석 연구원:
          • William D. Roberts
      • San Francisco, California, 미국, 94158
        • 모병
        • UCSF Medical Center-Mission Bay
        • 연락하다:
        • 수석 연구원:
          • Arun A. Rangaswami
    • Colorado
      • Aurora, Colorado, 미국, 80045
        • 모병
        • Children's Hospital Colorado
        • 수석 연구원:
          • Navin R. Pinto
        • 연락하다:
    • Connecticut
      • Hartford, Connecticut, 미국, 06106
        • 모병
        • Connecticut Children's Medical Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 860-545-9981
        • 수석 연구원:
          • Michael S. Isakoff
      • New Haven, Connecticut, 미국, 06520
        • 모병
        • Yale University
        • 연락하다:
        • 수석 연구원:
          • Farzana Pashankar
    • Delaware
      • Wilmington, Delaware, 미국, 19803
        • 모병
        • Alfred I duPont Hospital for Children
        • 연락하다:
        • 수석 연구원:
          • Sridhi Patel
    • District of Columbia
      • Washington D.C., District of Columbia, 미국, 20010
        • 모병
        • Children's National Medical Center
        • 수석 연구원:
          • Jeffrey S. Dome
        • 연락하다:
    • Florida
      • Fort Lauderdale, Florida, 미국, 33316
        • 모병
        • Broward Health Medical Center
        • 연락하다:
        • 수석 연구원:
          • Hector M. Rodriguez-Cortes
      • Fort Myers, Florida, 미국, 33908
        • 모병
        • Golisano Children's Hospital of Southwest Florida
        • 연락하다:
        • 수석 연구원:
          • Emad K. Salman
      • Gainesville, Florida, 미국, 32610
        • 모병
        • UF Health Cancer Institute - Gainesville
        • 연락하다:
        • 수석 연구원:
          • Brian Stover
      • Hollywood, Florida, 미국, 33021
        • 모병
        • Memorial Regional Hospital/Joe DiMaggio Children's Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 954-265-1847
          • 이메일: OHR@mhs.net
        • 수석 연구원:
          • Iftikhar Hanif
      • Jacksonville, Florida, 미국, 32207
        • 모병
        • Nemours Children's Clinic-Jacksonville
        • 연락하다:
        • 수석 연구원:
          • Sridhi Patel
      • Miami, Florida, 미국, 33155
        • 모병
        • Nicklaus Children's Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 888-624-2778
        • 수석 연구원:
          • Ziad A. Khatib
      • Miami, Florida, 미국, 33136
        • 모병
        • University of Miami Miller School of Medicine-Sylvester Cancer Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 305-243-2647
        • 수석 연구원:
          • Meghan McCormick
      • Orlando, Florida, 미국, 32806
        • 모병
        • Arnold Palmer Hospital for Children
        • 연락하다:
        • 수석 연구원:
          • Zhongbo Hu
      • Orlando, Florida, 미국, 32827
        • 모병
        • Nemours Children's Hospital
        • 연락하다:
        • 수석 연구원:
          • Sridhi Patel
      • Orlando, Florida, 미국, 32803
        • 모병
        • AdventHealth Orlando
        • 연락하다:
        • 수석 연구원:
          • Fouad M. Hajjar
      • St. Petersburg, Florida, 미국, 33701
        • 모병
        • Johns Hopkins All Children's Hospital
        • 연락하다:
        • 수석 연구원:
          • Jennifer B. Dean
      • West Palm Beach, Florida, 미국, 33407
        • 모병
        • Saint Mary's Medical Center
        • 수석 연구원:
          • Matthew D. Ramirez
        • 연락하다:
          • Site Public Contact
          • 전화번호: 561-822-4745
    • Georgia
      • Atlanta, Georgia, 미국, 30329
        • 모병
        • Children's Healthcare of Atlanta - Arthur M Blank Hospital
        • 수석 연구원:
          • William T. Cash
        • 연락하다:
      • Savannah, Georgia, 미국, 31404
        • 모병
        • Memorial Health University Medical Center
        • 연락하다:
        • 수석 연구원:
          • James N. Yarnall
    • Hawaii
      • Honolulu, Hawaii, 미국, 96826
        • 모병
        • Kapiolani Medical Center for Women and Children
        • 연락하다:
          • Site Public Contact
          • 전화번호: 808-983-6090
        • 수석 연구원:
          • Wade T. Kyono
    • Illinois
      • Chicago, Illinois, 미국, 60611
        • 모병
        • Lurie Children's Hospital-Chicago
        • 연락하다:
          • Site Public Contact
          • 전화번호: 773-880-4562
        • 수석 연구원:
          • Elizabeth A. Sokol
      • Chicago, Illinois, 미국, 60637
        • 모병
        • University of Chicago Comprehensive Cancer Center
        • 연락하다:
        • 수석 연구원:
          • Ami V. Desai
      • Chicago, Illinois, 미국, 60612
        • 모병
        • University of Illinois
        • 연락하다:
          • Site Public Contact
          • 전화번호: 312-355-3046
        • 수석 연구원:
          • Dipti S. Dighe
      • Oak Lawn, Illinois, 미국, 60453
        • 모병
        • Advocate Children's Hospital-Oak Lawn
        • 연락하다:
          • Site Public Contact
          • 전화번호: 847-723-7570
        • 수석 연구원:
          • Rebecca E. McFall
      • Park Ridge, Illinois, 미국, 60068
      • Peoria, Illinois, 미국, 61637
      • Springfield, Illinois, 미국, 62702
        • 모병
        • Southern Illinois University School of Medicine
        • 연락하다:
          • Site Public Contact
          • 전화번호: 217-545-7929
        • 수석 연구원:
          • Gregory P. Brandt
    • Indiana
      • Indianapolis, Indiana, 미국, 46202
        • 모병
        • Riley Hospital for Children
        • 연락하다:
          • Site Public Contact
          • 전화번호: 800-248-1199
        • 수석 연구원:
          • Marissa Just
      • Indianapolis, Indiana, 미국, 46260
        • 모병
        • Ascension Saint Vincent Indianapolis Hospital
        • 연락하다:
        • 수석 연구원:
          • Bassem I. Razzouk
    • Iowa
      • Des Moines, Iowa, 미국, 50309
        • 모병
        • Blank Children's Hospital
        • 연락하다:
        • 수석 연구원:
          • Samantha L. Mallory
      • Iowa City, Iowa, 미국, 52242
        • 모병
        • University of Iowa/Holden Comprehensive Cancer Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 800-237-1225
        • 수석 연구원:
          • Andrew P. Groves
    • Kansas
      • Wichita, Kansas, 미국, 67214
        • 모병
        • Wesley Medical Center
        • 연락하다:
        • 수석 연구원:
          • Nathan S. Hall
    • Kentucky
      • Lexington, Kentucky, 미국, 40536
        • 모병
        • University of Kentucky/Markey Cancer Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 859-257-3379
        • 수석 연구원:
          • James T. Badgett
      • Louisville, Kentucky, 미국, 40202
        • 모병
        • Norton Children's Hospital
        • 연락하다:
        • 수석 연구원:
          • Michael J. Ferguson
    • Louisiana
      • New Orleans, Louisiana, 미국, 70118
        • 모병
        • Children's Hospital New Orleans
        • 수석 연구원:
          • Maria C. Velez-Yanguas
        • 연락하다:
          • Site Public Contact
          • 전화번호: 504-894-5377
    • Maine
      • Bangor, Maine, 미국, 04401
        • 모병
        • Eastern Maine Medical Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 207-973-4274
        • 수석 연구원:
          • Daniel L. Callaway
      • Scarborough, Maine, 미국, 04074
        • 모병
        • Maine Children's Cancer Program
        • 수석 연구원:
          • Sei-Gyung K. Sze
        • 연락하다:
    • Maryland
      • Baltimore, Maryland, 미국, 21287
        • 모병
        • Johns Hopkins University/Sidney Kimmel Cancer Center
        • 수석 연구원:
          • Allen R. Chen
        • 연락하다:
      • Baltimore, Maryland, 미국, 21215
        • 모병
        • Sinai Hospital of Baltimore
        • 수석 연구원:
          • Jason M. Fixler
        • 연락하다:
          • Site Public Contact
          • 전화번호: 410-601-9083
      • Baltimore, Maryland, 미국, 21201
        • 모병
        • University of Maryland/Greenebaum Cancer Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 800-888-8823
        • 수석 연구원:
          • Teresa A. York
      • Bethesda, Maryland, 미국, 20889-5600
        • 모병
        • Walter Reed National Military Medical Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 301-319-2100
        • 수석 연구원:
          • Kip R. Hartman
    • Massachusetts
      • Boston, Massachusetts, 미국, 02114
        • 모병
        • Massachusetts General Hospital Cancer Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 877-726-5130
        • 수석 연구원:
          • Lauren H. Boal
      • Boston, Massachusetts, 미국, 02215
        • 모병
        • Dana-Farber Cancer Institute
        • 연락하다:
          • Site Public Contact
          • 전화번호: 877-442-3324
        • 수석 연구원:
          • Suzanne Shusterman
    • Michigan
      • Ann Arbor, Michigan, 미국, 48109
        • 모병
        • C S Mott Children's Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 800-865-1125
        • 수석 연구원:
          • Rajen Mody
      • Detroit, Michigan, 미국, 48201
        • 정지된
        • Children's Hospital of Michigan
      • Grand Rapids, Michigan, 미국, 49503
        • 모병
        • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
        • 연락하다:
        • 수석 연구원:
          • Kathleen Y. Butler
      • Kalamazoo, Michigan, 미국, 49007
        • 모병
        • Bronson Methodist Hospital
        • 연락하다:
        • 수석 연구원:
          • Kathleen Y. Butler
      • Royal Oak, Michigan, 미국, 48073
        • 모병
        • Corewell Health Children's
        • 연락하다:
          • Site Public Contact
          • 전화번호: 248-551-7695
        • 수석 연구원:
          • Marie V. Nelson
    • Minnesota
      • Minneapolis, Minnesota, 미국, 55404
        • 모병
        • Children's Hospitals and Clinics of Minnesota - Minneapolis
        • 수석 연구원:
          • Michael K. Richards
        • 연락하다:
      • Minneapolis, Minnesota, 미국, 55455
        • 모병
        • University of Minnesota/Masonic Cancer Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 612-624-2620
        • 수석 연구원:
          • Robin L. Williams
      • Rochester, Minnesota, 미국, 55905
        • 모병
        • Mayo Clinic in Rochester
        • 연락하다:
          • Site Public Contact
          • 전화번호: 855-776-0015
        • 수석 연구원:
          • Peter Schoettler
    • Mississippi
      • Jackson, Mississippi, 미국, 39216
        • 모병
        • University of Mississippi Medical Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 601-815-6700
        • 수석 연구원:
          • Amanda Strobel
    • Missouri
      • Columbia, Missouri, 미국, 65212
        • 모병
        • University of Missouri Children's Hospital
        • 수석 연구원:
          • Barbara A. Gruner
        • 연락하다:
      • Kansas City, Missouri, 미국, 64108
        • 모병
        • Children's Mercy Hospitals and Clinics
        • 수석 연구원:
          • Keith J. August
        • 연락하다:
      • St Louis, Missouri, 미국, 63110
        • 모병
        • Washington University School of Medicine
        • 연락하다:
        • 수석 연구원:
          • Frederick S. Huang
      • St Louis, Missouri, 미국, 63141
        • 모병
        • Mercy Hospital Saint Louis
        • 연락하다:
          • Site Public Contact
          • 전화번호: 314-251-7066
        • 수석 연구원:
          • Robin D. Hanson
    • Nebraska
      • Omaha, Nebraska, 미국, 68114
        • 모병
        • Children's Hospital and Medical Center of Omaha
        • 연락하다:
          • Site Public Contact
          • 전화번호: 402-955-3949
        • 수석 연구원:
          • Jill C. Beck
      • Omaha, Nebraska, 미국, 68198
        • 모병
        • University of Nebraska Medical Center
        • 연락하다:
        • 수석 연구원:
          • Jill C. Beck
    • Nevada
      • Las Vegas, Nevada, 미국, 89135
        • 모병
        • Alliance for Childhood Diseases/Cure 4 the Kids Foundation
        • 연락하다:
        • 수석 연구원:
          • Joseph L. Lasky
    • New Hampshire
      • Lebanon, New Hampshire, 미국, 03756
        • 모병
        • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
        • 수석 연구원:
          • Angela Ricci
        • 연락하다:
    • New Jersey
      • Hackensack, New Jersey, 미국, 07601
        • 모병
        • Hackensack University Medical Center
        • 수석 연구원:
          • Katharine Offer
        • 연락하다:
          • Site Public Contact
          • 전화번호: 551-996-2897
      • Morristown, New Jersey, 미국, 07960
        • 모병
        • Morristown Medical Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 973-971-5900
        • 수석 연구원:
          • Kathryn L. Laurie
      • New Brunswick, New Jersey, 미국, 08901
        • 모병
        • Saint Peter's University Hospital
        • 수석 연구원:
          • Nibal A. Zaghloul
        • 연락하다:
      • New Brunswick, New Jersey, 미국, 08903
        • 모병
        • Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 732-235-8675
        • 수석 연구원:
          • Nehal S. Parikh
      • Newark, New Jersey, 미국, 07112
        • 모병
        • Newark Beth Israel Medical Center
        • 연락하다:
        • 수석 연구원:
          • Teena Bhatla
      • Paterson, New Jersey, 미국, 07503
        • 모병
        • Saint Joseph's Regional Medical Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 973-754-2207
          • 이메일: HallL@sjhmc.org
        • 수석 연구원:
          • Alissa Kahn
    • New Mexico
      • Albuquerque, New Mexico, 미국, 87106
        • 정지된
        • University of New Mexico Cancer Center
    • New York
      • Albany, New York, 미국, 12208
        • 모병
        • Albany Medical Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 518-262-5513
        • 수석 연구원:
          • Lauren R. Weintraub
      • Buffalo, New York, 미국, 14263
        • 모병
        • Roswell Park Cancer Institute
        • 연락하다:
        • 수석 연구원:
          • Clare J. Twist
      • Mineola, New York, 미국, 11501
        • 모병
        • NYU Langone Hospital - Long Island
        • 연락하다:
        • 수석 연구원:
          • Chana L. Glasser
      • New Hyde Park, New York, 미국, 11040
        • 모병
        • The Steven and Alexandra Cohen Children's Medical Center of New York
        • 연락하다:
          • Site Public Contact
          • 전화번호: 718-470-3460
        • 수석 연구원:
          • Julie I. Krystal
      • New York, New York, 미국, 10032
        • 모병
        • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
        • 수석 연구원:
          • Nobuko Hijiya
        • 연락하다:
      • New York, New York, 미국, 10016
        • 모병
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone
        • 수석 연구원:
          • Elizabeth A. Raetz
        • 연락하다:
      • Rochester, New York, 미국, 14642
        • 모병
        • University of Rochester
        • 연락하다:
          • Site Public Contact
          • 전화번호: 585-275-5830
        • 수석 연구원:
          • Rafi R. Kazi
      • Syracuse, New York, 미국, 13210
        • 모병
        • State University of New York Upstate Medical University
        • 연락하다:
          • Site Public Contact
          • 전화번호: 315-464-5476
        • 수석 연구원:
          • Melanie A. Comito
      • The Bronx, New York, 미국, 10467
        • 모병
        • Montefiore Medical Center - Moses Campus
        • 연락하다:
        • 수석 연구원:
          • Alice Lee
      • Valhalla, New York, 미국, 10595
        • 모병
        • New York Medical College
        • 연락하다:
          • Site Public Contact
          • 전화번호: 914-594-3794
        • 수석 연구원:
          • Andrew J. Bellantoni
    • North Carolina
      • Asheville, North Carolina, 미국, 28801
      • Chapel Hill, North Carolina, 미국, 27599
        • 모병
        • UNC Lineberger Comprehensive Cancer Center
        • 연락하다:
        • 수석 연구원:
          • Thomas B. Alexander
      • Charlotte, North Carolina, 미국, 28203
        • 모병
        • Carolinas Medical Center/Levine Cancer Institute
        • 연락하다:
          • Site Public Contact
          • 전화번호: 800-804-9376
        • 수석 연구원:
          • Joel A. Kaplan
      • Charlotte, North Carolina, 미국, 28204
        • 모병
        • Novant Health Presbyterian Medical Center
        • 연락하다:
        • 수석 연구원:
          • Holly Edington
      • Durham, North Carolina, 미국, 27710
        • 모병
        • Duke University Medical Center
        • 수석 연구원:
          • Jessica M. Sun
        • 연락하다:
          • Site Public Contact
          • 전화번호: 888-275-3853
      • Greenville, North Carolina, 미국, 27834
        • 모병
        • East Carolina University
        • 연락하다:
        • 수석 연구원:
          • Andrea R. Whitfield
      • Winston-Salem, North Carolina, 미국, 27157
        • 모병
        • Wake Forest University Health Sciences
        • 연락하다:
          • Site Public Contact
          • 전화번호: 336-713-6771
        • 수석 연구원:
          • Sarah Supples
    • North Dakota
      • Fargo, North Dakota, 미국, 58122
    • Ohio
      • Akron, Ohio, 미국, 44308
        • 모병
        • Children's Hospital Medical Center of Akron
        • 연락하다:
          • Site Public Contact
          • 전화번호: 330-543-3193
        • 수석 연구원:
          • Lauren R. Draper
      • Cincinnati, Ohio, 미국, 45229
        • 모병
        • Cincinnati Children's Hospital Medical Center
        • 연락하다:
        • 수석 연구원:
          • Katherine M. Somers
      • Cleveland, Ohio, 미국, 44195
        • 모병
        • Cleveland Clinic Foundation
        • 연락하다:
        • 수석 연구원:
          • Matteo M. Trucco
      • Cleveland, Ohio, 미국, 44106
        • 모병
        • Rainbow Babies and Childrens Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 216-844-5437
        • 수석 연구원:
          • Duncan S. Stearns
      • Columbus, Ohio, 미국, 43205
      • Dayton, Ohio, 미국, 45404
        • 모병
        • Dayton Children's Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 800-228-4055
        • 수석 연구원:
          • Jordan M. Wright
      • Toledo, Ohio, 미국, 43606
        • 모병
        • ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
        • 연락하다:
        • 수석 연구원:
          • Jamie L. Dargart
    • Oklahoma
      • Oklahoma City, Oklahoma, 미국, 73104
        • 모병
        • University of Oklahoma Health Sciences Center
        • 연락하다:
        • 수석 연구원:
          • Rene Y. McNall-Knapp
      • Tulsa, Oklahoma, 미국, 74136
        • 모병
        • Saint Francis Children's Hospital
        • 수석 연구원:
          • Jill A. Salo
        • 연락하다:
          • Site Public Contact
          • 전화번호: 918-502-6720
    • Oregon
      • Portland, Oregon, 미국, 97227
        • 모병
        • Legacy Emanuel Children's Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 503-413-2560
        • 수석 연구원:
          • Jason M. Glover
      • Portland, Oregon, 미국, 97239
        • 모병
        • Oregon Health and Science University
        • 연락하다:
          • Site Public Contact
          • 전화번호: 503-494-1080
          • 이메일: trials@ohsu.edu
        • 수석 연구원:
          • Susan J. Lindemulder
    • Pennsylvania
      • Allentown, Pennsylvania, 미국, 18103
        • 모병
        • Lehigh Valley Hospital-Cedar Crest
        • 연락하다:
        • 수석 연구원:
          • Jacob A. Troutman
      • Danville, Pennsylvania, 미국, 17822
        • 모병
        • Geisinger Medical Center
        • 수석 연구원:
          • Jagadeesh Ramdas
        • 연락하다:
      • Philadelphia, Pennsylvania, 미국, 19104
        • 모병
        • Children's Hospital of Philadelphia
        • 수석 연구원:
          • Rochelle Bagatell
        • 연락하다:
      • Philadelphia, Pennsylvania, 미국, 19134
        • 모병
        • Saint Christopher's Hospital for Children
        • 연락하다:
          • Site Public Contact
          • 전화번호: 215-427-8991
        • 수석 연구원:
          • Gregory E. Halligan
      • Pittsburgh, Pennsylvania, 미국, 15224
        • 모병
        • Children's Hospital of Pittsburgh of UPMC
        • 연락하다:
        • 수석 연구원:
          • Jean M. Tersak
    • Rhode Island
      • Providence, Rhode Island, 미국, 02903
        • 모병
        • Rhode Island Hospital
        • 수석 연구원:
          • Bradley DeNardo
        • 연락하다:
          • Site Public Contact
          • 전화번호: 401-444-1488
    • South Carolina
      • Charleston, South Carolina, 미국, 29425
        • 모병
        • Medical University of South Carolina
        • 연락하다:
        • 수석 연구원:
          • Jacqueline M. Kraveka
      • Columbia, South Carolina, 미국, 29203
        • 모병
        • Prisma Health Richland Hospital
        • 수석 연구원:
          • Stuart L. Cramer
        • 연락하다:
      • Greenville, South Carolina, 미국, 29605
        • 모병
        • BI-LO Charities Children's Cancer Center
        • 수석 연구원:
          • Aniket Saha
        • 연락하다:
    • South Dakota
      • Sioux Falls, South Dakota, 미국, 57117-5134
    • Tennessee
      • Knoxville, Tennessee, 미국, 37916
        • 모병
        • East Tennessee Childrens Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 865-541-8266
        • 수석 연구원:
          • Susan E. Spiller
      • Memphis, Tennessee, 미국, 38105
        • 모병
        • Saint Jude Children's Research Hospital
        • 수석 연구원:
          • Sara M. Federico
        • 연락하다:
      • Nashville, Tennessee, 미국, 37232
        • 모병
        • Vanderbilt University/Ingram Cancer Center
        • 수석 연구원:
          • Daniel J. Benedetti
        • 연락하다:
          • Site Public Contact
          • 전화번호: 800-811-8480
      • Nashville, Tennessee, 미국, 37203
        • 모병
        • The Children's Hospital at TriStar Centennial
        • 연락하다:
          • Site Public Contact
          • 전화번호: 615-342-1919
        • 수석 연구원:
          • Clinton M. Carroll
    • Texas
      • Austin, Texas, 미국, 78723
      • Corpus Christi, Texas, 미국, 78411
        • 모병
        • Driscoll Children's Hospital
        • 연락하다:
        • 수석 연구원:
          • Nkechi I. Mba
      • Dallas, Texas, 미국, 75390
        • 모병
        • UT Southwestern/Simmons Cancer Center-Dallas
        • 수석 연구원:
          • Tanya C. Watt
        • 연락하다:
      • Dallas, Texas, 미국, 75230
        • 모병
        • Medical City Dallas Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 972-566-5588
        • 수석 연구원:
          • Maurizio L. Ghisoli
      • El Paso, Texas, 미국, 79905
        • 모병
        • El Paso Children's Hospital
        • 연락하다:
        • 수석 연구원:
          • Benjamin Carcamo
      • Fort Worth, Texas, 미국, 76104
      • Houston, Texas, 미국, 77030
        • 모병
        • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
        • 연락하다:
          • Site Public Contact
          • 전화번호: 713-798-1354
          • 이메일: burton@bcm.edu
        • 수석 연구원:
          • Jennifer H. Foster
      • Houston, Texas, 미국, 77030
        • 모병
        • UT MD Anderson Cancer Center
        • 연락하다:
        • 수석 연구원:
          • Najat C. Daw
      • Lubbock, Texas, 미국, 79410
        • 모병
        • Covenant Children's Hospital
        • 수석 연구원:
          • Kishor M. Bhende
        • 연락하다:
      • Lubbock, Texas, 미국, 79415
        • 모병
        • UMC Cancer Center / UMC Health System
        • 연락하다:
          • Site Public Contact
          • 전화번호: 806-775-8590
        • 수석 연구원:
          • Erin K. Barr
      • San Antonio, Texas, 미국, 78207
        • 모병
        • Children's Hospital of San Antonio
        • 연락하다:
        • 수석 연구원:
          • Julie Voeller
      • San Antonio, Texas, 미국, 78229
        • 모병
        • University of Texas Health Science Center at San Antonio
        • 연락하다:
        • 수석 연구원:
          • Aaron J. Sugalski
      • San Antonio, Texas, 미국, 78229
        • 모병
        • Methodist Children's Hospital of South Texas
        • 연락하다:
        • 수석 연구원:
          • Jose M. Esquilin
    • Utah
      • Salt Lake City, Utah, 미국, 84113
        • 모병
        • Primary Children's Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 801-585-5270
        • 수석 연구원:
          • Leonora R. Slatnick
    • Vermont
      • Burlington, Vermont, 미국, 05405
        • 모병
        • University of Vermont and State Agricultural College
        • 연락하다:
          • Site Public Contact
          • 전화번호: 802-656-8990
          • 이메일: rpo@uvm.edu
        • 수석 연구원:
          • Jessica L. Heath
    • Virginia
      • Charlottesville, Virginia, 미국, 22908
      • Portsmouth, Virginia, 미국, 23708-2197
        • 모병
        • Naval Medical Center - Portsmouth
        • 연락하다:
          • Site Public Contact
          • 전화번호: 757-953-5939
        • 수석 연구원:
          • Karin Brockman
    • Washington
      • Seattle, Washington, 미국, 98105
        • 모병
        • Seattle Children's Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 866-987-2000
        • 수석 연구원:
          • Sarah E. Leary
      • Spokane, Washington, 미국, 99204
        • 모병
        • Providence Sacred Heart Medical Center and Children's Hospital
        • 연락하다:
        • 수석 연구원:
          • Judy L. Felgenhauer
      • Tacoma, Washington, 미국, 98405
        • 모병
        • Mary Bridge Children's Hospital and Health Center
        • 연락하다:
        • 수석 연구원:
          • Robert G. Irwin
    • West Virginia
      • Huntington, West Virginia, 미국, 25701
        • 모병
        • Edwards Comprehensive Cancer Center
        • 수석 연구원:
          • Mark A. Ranalli
        • 연락하다:
      • Morgantown, West Virginia, 미국, 26506
        • 모병
        • West Virginia University Healthcare
        • 연락하다:
        • 수석 연구원:
          • Ashley E. Meyer
    • Wisconsin
      • Green Bay, Wisconsin, 미국, 54301
        • 정지된
        • Saint Vincent Hospital Cancer Center Green Bay
      • Madison, Wisconsin, 미국, 53792
        • 모병
        • University of Wisconsin Carbone Cancer Center - University Hospital
        • 연락하다:
        • 수석 연구원:
          • Margo L. Hoover-Regan
      • Marshfield, Wisconsin, 미국, 54449
      • Milwaukee, Wisconsin, 미국, 53226
        • 모병
        • Children's Hospital of Wisconsin
        • 수석 연구원:
          • Angela Steineck
        • 연락하다:
          • Site Public Contact
          • 전화번호: 414-955-4727
          • 이메일: MACCCTO@mcw.edu
      • Québec, 캐나다, G1V 4G2
        • 모병
        • CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
        • 수석 연구원:
          • Bruno Michon
        • 연락하다:
    • Alberta
      • Calgary, Alberta, 캐나다, T3B 6A8
        • 모병
        • Alberta Children's Hospital
        • 연락하다:
        • 수석 연구원:
          • Victor A. Lewis
      • Edmonton, Alberta, 캐나다, T6G 2B7
        • 모병
        • University of Alberta Hospital
        • 연락하다:
        • 수석 연구원:
          • Sarah J. McKillop
    • British Columbia
      • Vancouver, British Columbia, 캐나다, V6H 3V4
        • 모병
        • British Columbia Children's Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 6477 604-875-2345
        • 수석 연구원:
          • Rebecca J. Deyell
    • Manitoba
      • Winnipeg, Manitoba, 캐나다, R3E 0V9
        • 모병
        • CancerCare Manitoba
        • 연락하다:
        • 수석 연구원:
          • Stephanie M. Villeneuve
    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, 캐나다, A1B 3V6
        • 모병
        • Janeway Child Health Centre
        • 수석 연구원:
          • Lisa A. Goodyear
        • 연락하다:
    • Nova Scotia
      • Halifax, Nova Scotia, 캐나다, B3K 6R8
        • 모병
        • IWK Health Centre
        • 연락하다:
        • 수석 연구원:
          • Chelsea Ash
    • Ontario
      • Hamilton, Ontario, 캐나다, L8N 3Z5
        • 모병
        • McMaster Children's Hospital at Hamilton Health Sciences
        • 연락하다:
          • Site Public Contact
          • 전화번호: 905-521-2100
        • 수석 연구원:
          • Uma H. Athale
      • London, Ontario, 캐나다, N6A 5W9
        • 모병
        • Children's Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 519-685-8306
        • 수석 연구원:
          • Shayna M. Zelcer
      • Ottawa, Ontario, 캐나다, K1H 8L1
        • 모병
        • Children's Hospital of Eastern Ontario
        • 연락하다:
          • Site Public Contact
          • 전화번호: 613-737-7600
        • 수석 연구원:
          • Donna L. Johnston
      • Toronto, Ontario, 캐나다, M5G 1X8
        • 모병
        • Hospital for Sick Children
        • 연락하다:
        • 수석 연구원:
          • Daniel A. Morgenstern
    • Quebec
      • Montreal, Quebec, 캐나다, H3H 1P3
        • 모병
        • The Montreal Children's Hospital of the MUHC
        • 연락하다:
        • 수석 연구원:
          • Stephanie Mourad
      • Montreal, Quebec, 캐나다, H3T 1C5
        • 모병
        • Centre Hospitalier Universitaire Sainte-Justine
        • 수석 연구원:
          • Monia Marzouki
        • 연락하다:
      • Sherbrooke, Quebec, 캐나다, J1H 5N4
        • 모병
        • Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
        • 연락하다:
        • 수석 연구원:
          • Stephanie Vairy
    • Saskatchewan
      • Saskatoon, Saskatchewan, 캐나다, S7N 0W8
        • 모병
        • Jim Pattison Children's Hospital
        • 수석 연구원:
          • Kathleen Felton
        • 연락하다:
      • San Juan, 푸에르토 리코, 00926
        • 모병
        • University Pediatric Hospital
        • 연락하다:
          • Site Public Contact
          • 전화번호: 787-474-0333
        • 수석 연구원:
          • Maria E. Echevarria
    • New South Wales
      • Randwick, New South Wales, 호주, 2031
        • 모병
        • Sydney Children's Hospital
        • 수석 연구원:
          • Draga Barbaric
        • 연락하다:
          • Site Public Contact
          • 전화번호: (02) 9382-1721
      • Westmead, New South Wales, 호주, 2145
        • 모병
        • The Children's Hospital at Westmead
        • 연락하다:
          • Site Public Contact
          • 전화번호: 61-2-9845 1400
        • 수석 연구원:
          • Bhavna Padhye
    • Queensland
      • South Brisbane, Queensland, 호주, 4101
        • 모병
        • Queensland Children's Hospital
        • 수석 연구원:
          • Steven A. Foresto
        • 연락하다:
          • Site Public Contact
          • 전화번호: 61 7 3068 1111
    • Victoria
      • Parkville, Victoria, 호주, 3052
        • 모병
        • Royal Children's Hospital
        • 수석 연구원:
          • Martin A. Campbell
        • 연락하다:
    • Western Australia
      • Perth, Western Australia, 호주, 6009

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

30년 이하 (어린이, 성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Patients must be enrolled on APEC14B1 and have consented to testing through the Molecular Characterization Initiative (MCI), prior to enrollment on ANBL2131

  • ≤ 30 years at the time of initial diagnosis with high-risk disease

  • * Must have a diagnosis of neuroblastoma (NBL) or ganglioneuroblastoma (nodular) verified by tumor pathology analysis or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamines

    • Newly diagnosed, high risk neuroblastoma (HRNBL) defined as one of the following:

      • Any age with International Neuroblastoma Risk Group (INRG) Stage L2, MS, or M and MYCN amplification
      • Age ≥ 547 days and INRG stage M regardless of biologic features (clinical MYCN testing not required prior to enrollment)
      • Any age initially diagnosed with INRG Stage L1 MYCN amplified NBL who have progressed to stage M without systemic chemotherapy
      • Age ≥ 547 days of age initially diagnosed with INRG Stage L1, L2, or MS who have progressed to stage M without systemic chemotherapy (clinical MYCN testing not required prior to enrollment)
  • Patients must have a body surface area (BSA) ≥ 0.25 m^2

  • No prior anti-cancer therapy except as outlined below:

    • Patients initially recognized to have high-risk disease treated with topotecan/cyclophosphamide initiated on an emergent basis and within allowed timing, and with consent
    • Patients observed or treated with a single cycle of chemotherapy per a low or intermediate risk neuroblastoma regimen (e.g., as per ANBL0531, ANBL1232 or similar) for what initially appeared to be non-high-risk disease but subsequently found to meet the criteria
    • Patients who received localized emergency radiation to sites of life threatening or function-threatening disease prior to or immediately after establishment of the definitive diagnosis
  • Human immunodeficiency virus (HIV) -infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial

  • A serum creatinine based on age/sex as follows:

    • 1 month to < 6 months: Male 0.4 mg/dL and female 0.4mg/dL

    • 6 months to < 1 year: Male 0.5 mg/dL and female 0.5 mg/dL

    • 1 to < 2 years: Male 0.6 mg/dL and female 0.6 mg/dL

    • 2 to < 6 years: Male 0.8 mg/dL and female 0.8 mg/dL

    • 6 to < 10 years: Male 1 mg/dL and female 1 mg/dL

    • 10 to < 13 years: Male 1.2 mg/dL and female 1.2 mg/dL

    • 13 to < 16 years: Male 1.5 mg/dL and female 1.4 mg/dL

    • ≥ 16 years: Male 1.7 mg/dL and female 1.4 mg/dL

      • The threshold creatinine values were derived from the Schwartz formula for estimating glomerular filtration rate (GFR) utilizing child length and stature data published by the Centers for Disease Control (CDC)
    • or a 24-hour urine creatinine clearance ≥ 70 mL/min/1.73 m^2 or

    • or a GFR ≥ 70 mL/min/1.73 m^2. GFR must be performed using direct measurement with a nuclear blood sampling method or direct small molecule clearance method (iothalamate or other molecule per institutional standard)

      • Note: Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates are not acceptable for determining eligibility
  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age

  • Serum glutamic pyruvic transaminase (SGPT) (Alanine aminotransferase [ALT]) ≤ 10 x ULN*

    • Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
  • * Shortening fraction of ≥ 27% by echocardiogram, or

    • Ejection fraction of ≥ 50% by echocardiogram or radionuclide angiogram
  • Ability to tolerate Peripheral Blood Stem Cell (PBSC) collection:

No known contraindication to PBSC collection. Examples of contraindications might be a weight or size less than the collecting institution finds feasible, or a physical condition that would limit the ability of the child to undergo apheresis catheter placement (if necessary) and/or the apheresis procedure

Exclusion Criteria:

  • Patients who are 365-546 days of age with INRG Stage M and MYCN non-amplified NBL, irrespective of additional biologic features
  • Patients ≥ 547 days of age with INRG Stage L2, MYCN non-amplified NBL, regardless of additional biologic features
  • Patients with known bone marrow failure syndromes
  • Patients on chronic immunosuppressive medications (e.g., tacrolimus, cyclosporine, corticosteroids) for reasons other than prevention/treatment of allergic reactions and adrenal replacement therapy are not eligible. Topical and inhaled corticosteroids are acceptable
  • Patients with a primary immunodeficiency syndrome who require ongoing immune globulin replacement therapy
  • Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required prior to enrollment for female patients of childbearing potential
  • Lactating females who plan to breastfeed their infants
  • Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation
  • All patients and/or their parents or legal guardians must sign a written informed consent
  • All institutional, food and drug administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: Arm A (SOC treatment)

See detailed description

Given IV

다른 이름들:
  • 폭발탄
  • 카르보플라트
  • 카보플라틴 헥살
  • 카르보플라티노
  • 카보플라티넘
  • 카르보신
  • 카보솔
  • 카보텍
  • CBDCA
  • 디스플라타
  • 에르카르
  • JM-8
  • 닐로린
  • 노보플라티넘
  • 파라플라틴
  • 파라플라틴 AQ
  • 플라틴와스
  • 리보카르보
  • JM8

Given IV

다른 이름들:
  • 사이톡산
  • CTX
  • (-)-시클로포스파미드
  • 2H-1,3,2-옥사자포스포린, 2-[비스(2-클로로에틸)아미노]테트라하이드로-, 2-옥사이드, 일수화물
  • 칼록산
  • 시클로포스파미다
  • 시클로포스파마이드
  • 시클록살
  • 클라펜
  • CP 일수화물
  • CYCLO 셀
  • 사이클로블라스틴
  • 사이클로포스팜
  • 사이클로포스파미드 일수화물
  • 사이클로포스파미둠
  • 시클로포스판
  • 사이클로포스판
  • 시클로포스파늄
  • 사이클로스틴
  • 사이토포스판
  • 포스파세론
  • 제녹살
  • 제눅살
  • 레독시나
  • 미톡산
  • 네오사르
  • 리바이뮨
  • 실클로포스파미드
  • WR-138719
  • 아스타 B 518
  • B-518
  • B518
  • WR 138719
  • WR138719
  • 프린도빅스

Given IV

다른 이름들:
  • CDDP
  • 시스-디암민디클로리도백금
  • 시스마플라트
  • 시스플라티넘
  • 네오플라틴
  • 플라티놀
  • 아비플라틴
  • 블라스톨렘
  • 브리플라틴
  • 시스-디아민-디클로로백금
  • 시스-디아민디클로로 백금(II)
  • 시스-디아민디클로로백금
  • 시스-디클로로암민 백금(II)
  • 시스-백금 디아민 디클로라이드
  • 시스-백금
  • 시스-백금 II
  • 시스-백금 II 디아민 디클로라이드
  • 시스플라티나
  • 시스플라틸
  • 치토플라티노
  • 시토신
  • DDP
  • 레더플라틴
  • 메타플라틴
  • Peyrone의 염화물
  • 페이론의 소금
  • 플라시스
  • 플라스티스틸
  • 플라타민
  • 플라티블라스틴
  • 플라티블라스틴-S
  • 플래티넥스
  • 플라티놀-AQ
  • 플라티놀-AQ VHA 플러스
  • 플라티녹산
  • 백금
  • 백금 디암미노디클로라이드
  • 플라티란
  • 플라티스틴
  • 플라토신

Undergo bone marrow biopsy

다른 이름들:
  • 골수 생검
  • 생검, 골수

Given IV

다른 이름들:
  • 아드리아블라스틴
  • 하이드록시다우노마이신
  • 하이드록실 다우노루비신
  • 하이드록실다우노루비신

Given IV

다른 이름들:
  • VCR
  • 류로크리스틴
  • 빈크리스틴
  • LCR

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 의료영상, 자기공명 / 핵자기공명
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 핵자기공명영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI

Undergo ECHO

다른 이름들:
  • 심초음파
  • EC

Undergo MUGA

다른 이름들:
  • 혈액 풀 스캔
  • 평형 방사성핵종 혈관조영술
  • 게이티드 혈액 풀 이미징
  • 무가
  • 방사성핵종 뇌실조영술
  • RNVG
  • SYMA 스캐닝
  • 동기화된 다중 게이트 수집 스캐닝
  • 무가 스캔
  • 다중 게이트 획득 스캔
  • 방사성핵종 뇌실도 스캔
  • 게이트 하트 풀 스캔
  • RNV 스캔

Undergo bone marrow aspiration

Given IV

다른 이름들:
  • 데메틸 에피포도필로톡신 에틸리딘 글루코사이드
  • 에펙
  • 라셋
  • 토포사르
  • 베페시드
  • 부사장 16
  • 부사장 16-213
  • VP-16
  • VP-16-213
  • VP16
  • VP 16213
  • VP-16213
  • VP16213

Undergo CT scan

다른 이름들:
  • CT
  • 고양이
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • 전산화 단층 촬영
  • CT 스캔
  • 단층 촬영
  • 컴퓨터 축 단층 촬영(시술)
  • 컴퓨터 단층촬영(CT) 스캔
  • 진단 CAT 스캔
  • 진단 CAT 스캔 서비스 유형

Given IV

다른 이름들:
  • 히캄파민
  • 토포테칸 락톤

Undergo radiation therapy

다른 이름들:
  • 암 방사선 요법
  • ENERGY_TYPE
  • 비추다
  • 조사
  • 방사능
  • 방사선 요법, NOS
  • 방사선 요법
  • RT
  • 치료, 방사선
  • 에너지 종류

Undergo blood and urine sample collection

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집
  • 샘플 수집

Ancillary studies

Given IV

다른 이름들:
  • CB-3025
  • 엘팜
  • L-사르콜리신
  • 알라닌 질소 머스타드
  • L-페닐알라닌 머스타드
  • L-사콜리신 페닐알라닌 머스타드
  • L-사르콜라이신
  • 멜파라눔
  • 페닐알라닌 머스타드
  • 페닐알라닌 질소 머스타드
  • 사코클로린
  • 사르콜리신
  • WR-19813
  • 간 주사 전달 시스템용 Melphalan

Given IV

Given IV

다른 이름들:
  • 테파디나
  • 온코티오테파
  • 스테파
  • 테스파
  • 테스파민
  • TSPA
  • 1,1',1''-포스피노티오일리딘트리사지리딘
  • 기로스탄
  • N,N', N''-트리에틸렌티오포스포르아미드
  • 티오-테파
  • 티오포스파마이드
  • 티오포질
  • 티오포스포르아미드
  • 티오테프
  • 티포실
  • 티오 테프
  • 트리에틸렌 티오포스포르아미드
  • 트리에틸렌티오포스포르아미드
  • 트리스(1-아지리디닐)포스핀 설파이드
  • WR45312
  • 티오포스포아미드
  • SH 105
  • SH-105
  • SH105
  • 테필루트

Given IV

다른 이름들:
  • Ch14.18
  • 카르지바
  • Ch 14.18UTC
  • MOAB Ch14.18
  • 단클론항체 Ch14.18
  • 유니툭신
  • 디누툭시맙 베타

Undergo FDG PET

다른 이름들:
  • FDG PET/CT

Undergo stem cell infusion

다른 이름들:
  • 조혈모세포이식
  • HCT
  • 줄기 세포 이식
  • 조혈모세포 주입
  • SCT
  • 줄기 세포 이식, NOS
  • 조혈 줄기세포 이식

Given PO

다른 이름들:
  • 앰존스팀
  • 시스테인
  • 클라라비스
  • 소트렛
  • 13-시스 레티노산
  • 13-시스-레티노에이트
  • 13-시스-레티노산
  • 13-시스-비타민 A 산
  • 13-cRA
  • 앱소리카
  • 정확하다
  • 어큐테인
  • 시스-레티노산
  • 이소트레티노이늄
  • 이소트렉스
  • 이소트렉신
  • 묘리산
  • 네오비타민 A
  • 네오비타민 A 산
  • 오라타네
  • 레티노산-13-시스
  • 롬 4-3780
  • Ro-4-3780
  • 로아큐탄
  • 제나탄

Undergo apheresis

다른 이름들:
  • 백혈구 분리술
  • 치료 백혈구성분채집술
  • 백혈구 흡착 성분채집술
  • 백혈구 감소 성분채집술

Undergo I-MIBG scan

다른 이름들:
  • 뉴멕시코
  • 핵 의학
  • 핵 의학 스캔
  • 방사선 촬영
  • 방사성 핵종 스캐닝
  • 주사
  • 신티그래피
  • 감마 스캔

Given PO or via NG or G tube

다른 이름들:
  • 테모다르
  • SCH 52365
  • 테모달
  • 템캐드
  • 메타졸라스톤
  • RP-46161
  • 테모메닥
  • TMZ
  • CCRG-81045
  • 이미다조[5,1-d]-1,2,3,5-테트라진-8-카르복스아미드, 3,4-디하이드로-3-메틸-4-옥소-
  • 엠앤비 39831
  • 글리오템
  • 테미졸

Undergo tumor resection surgery

실험적: Arm B (Dinutuximab in induction)

See detailed description

Given IV

다른 이름들:
  • 폭발탄
  • 카르보플라트
  • 카보플라틴 헥살
  • 카르보플라티노
  • 카보플라티넘
  • 카르보신
  • 카보솔
  • 카보텍
  • CBDCA
  • 디스플라타
  • 에르카르
  • JM-8
  • 닐로린
  • 노보플라티넘
  • 파라플라틴
  • 파라플라틴 AQ
  • 플라틴와스
  • 리보카르보
  • JM8

Given IV

다른 이름들:
  • 사이톡산
  • CTX
  • (-)-시클로포스파미드
  • 2H-1,3,2-옥사자포스포린, 2-[비스(2-클로로에틸)아미노]테트라하이드로-, 2-옥사이드, 일수화물
  • 칼록산
  • 시클로포스파미다
  • 시클로포스파마이드
  • 시클록살
  • 클라펜
  • CP 일수화물
  • CYCLO 셀
  • 사이클로블라스틴
  • 사이클로포스팜
  • 사이클로포스파미드 일수화물
  • 사이클로포스파미둠
  • 시클로포스판
  • 사이클로포스판
  • 시클로포스파늄
  • 사이클로스틴
  • 사이토포스판
  • 포스파세론
  • 제녹살
  • 제눅살
  • 레독시나
  • 미톡산
  • 네오사르
  • 리바이뮨
  • 실클로포스파미드
  • WR-138719
  • 아스타 B 518
  • B-518
  • B518
  • WR 138719
  • WR138719
  • 프린도빅스

Given IV

다른 이름들:
  • CDDP
  • 시스-디암민디클로리도백금
  • 시스마플라트
  • 시스플라티넘
  • 네오플라틴
  • 플라티놀
  • 아비플라틴
  • 블라스톨렘
  • 브리플라틴
  • 시스-디아민-디클로로백금
  • 시스-디아민디클로로 백금(II)
  • 시스-디아민디클로로백금
  • 시스-디클로로암민 백금(II)
  • 시스-백금 디아민 디클로라이드
  • 시스-백금
  • 시스-백금 II
  • 시스-백금 II 디아민 디클로라이드
  • 시스플라티나
  • 시스플라틸
  • 치토플라티노
  • 시토신
  • DDP
  • 레더플라틴
  • 메타플라틴
  • Peyrone의 염화물
  • 페이론의 소금
  • 플라시스
  • 플라스티스틸
  • 플라타민
  • 플라티블라스틴
  • 플라티블라스틴-S
  • 플래티넥스
  • 플라티놀-AQ
  • 플라티놀-AQ VHA 플러스
  • 플라티녹산
  • 백금
  • 백금 디암미노디클로라이드
  • 플라티란
  • 플라티스틴
  • 플라토신

Undergo bone marrow biopsy

다른 이름들:
  • 골수 생검
  • 생검, 골수

Given IV

다른 이름들:
  • 아드리아블라스틴
  • 하이드록시다우노마이신
  • 하이드록실 다우노루비신
  • 하이드록실다우노루비신

Given IV

다른 이름들:
  • VCR
  • 류로크리스틴
  • 빈크리스틴
  • LCR

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 의료영상, 자기공명 / 핵자기공명
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 핵자기공명영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI

Undergo ECHO

다른 이름들:
  • 심초음파
  • EC

Undergo MUGA

다른 이름들:
  • 혈액 풀 스캔
  • 평형 방사성핵종 혈관조영술
  • 게이티드 혈액 풀 이미징
  • 무가
  • 방사성핵종 뇌실조영술
  • RNVG
  • SYMA 스캐닝
  • 동기화된 다중 게이트 수집 스캐닝
  • 무가 스캔
  • 다중 게이트 획득 스캔
  • 방사성핵종 뇌실도 스캔
  • 게이트 하트 풀 스캔
  • RNV 스캔

Undergo bone marrow aspiration

Given IV

다른 이름들:
  • 데메틸 에피포도필로톡신 에틸리딘 글루코사이드
  • 에펙
  • 라셋
  • 토포사르
  • 베페시드
  • 부사장 16
  • 부사장 16-213
  • VP-16
  • VP-16-213
  • VP16
  • VP 16213
  • VP-16213
  • VP16213

Undergo CT scan

다른 이름들:
  • CT
  • 고양이
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • 전산화 단층 촬영
  • CT 스캔
  • 단층 촬영
  • 컴퓨터 축 단층 촬영(시술)
  • 컴퓨터 단층촬영(CT) 스캔
  • 진단 CAT 스캔
  • 진단 CAT 스캔 서비스 유형

Given IV

다른 이름들:
  • 히캄파민
  • 토포테칸 락톤

Undergo radiation therapy

다른 이름들:
  • 암 방사선 요법
  • ENERGY_TYPE
  • 비추다
  • 조사
  • 방사능
  • 방사선 요법, NOS
  • 방사선 요법
  • RT
  • 치료, 방사선
  • 에너지 종류

Undergo blood and urine sample collection

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집
  • 샘플 수집

Ancillary studies

Given IV

다른 이름들:
  • CB-3025
  • 엘팜
  • L-사르콜리신
  • 알라닌 질소 머스타드
  • L-페닐알라닌 머스타드
  • L-사콜리신 페닐알라닌 머스타드
  • L-사르콜라이신
  • 멜파라눔
  • 페닐알라닌 머스타드
  • 페닐알라닌 질소 머스타드
  • 사코클로린
  • 사르콜리신
  • WR-19813
  • 간 주사 전달 시스템용 Melphalan

Given IV

Given IV

다른 이름들:
  • 테파디나
  • 온코티오테파
  • 스테파
  • 테스파
  • 테스파민
  • TSPA
  • 1,1',1''-포스피노티오일리딘트리사지리딘
  • 기로스탄
  • N,N', N''-트리에틸렌티오포스포르아미드
  • 티오-테파
  • 티오포스파마이드
  • 티오포질
  • 티오포스포르아미드
  • 티오테프
  • 티포실
  • 티오 테프
  • 트리에틸렌 티오포스포르아미드
  • 트리에틸렌티오포스포르아미드
  • 트리스(1-아지리디닐)포스핀 설파이드
  • WR45312
  • 티오포스포아미드
  • SH 105
  • SH-105
  • SH105
  • 테필루트

Given IV

다른 이름들:
  • Ch14.18
  • 카르지바
  • Ch 14.18UTC
  • MOAB Ch14.18
  • 단클론항체 Ch14.18
  • 유니툭신
  • 디누툭시맙 베타

Undergo FDG PET

다른 이름들:
  • FDG PET/CT

Undergo stem cell infusion

다른 이름들:
  • 조혈모세포이식
  • HCT
  • 줄기 세포 이식
  • 조혈모세포 주입
  • SCT
  • 줄기 세포 이식, NOS
  • 조혈 줄기세포 이식

Given PO

다른 이름들:
  • 앰존스팀
  • 시스테인
  • 클라라비스
  • 소트렛
  • 13-시스 레티노산
  • 13-시스-레티노에이트
  • 13-시스-레티노산
  • 13-시스-비타민 A 산
  • 13-cRA
  • 앱소리카
  • 정확하다
  • 어큐테인
  • 시스-레티노산
  • 이소트레티노이늄
  • 이소트렉스
  • 이소트렉신
  • 묘리산
  • 네오비타민 A
  • 네오비타민 A 산
  • 오라타네
  • 레티노산-13-시스
  • 롬 4-3780
  • Ro-4-3780
  • 로아큐탄
  • 제나탄

Undergo apheresis

다른 이름들:
  • 백혈구 분리술
  • 치료 백혈구성분채집술
  • 백혈구 흡착 성분채집술
  • 백혈구 감소 성분채집술

Undergo I-MIBG scan

다른 이름들:
  • 뉴멕시코
  • 핵 의학
  • 핵 의학 스캔
  • 방사선 촬영
  • 방사성 핵종 스캐닝
  • 주사
  • 신티그래피
  • 감마 스캔

Given PO or via NG or G tube

다른 이름들:
  • 테모다르
  • SCH 52365
  • 테모달
  • 템캐드
  • 메타졸라스톤
  • RP-46161
  • 테모메닥
  • TMZ
  • CCRG-81045
  • 이미다조[5,1-d]-1,2,3,5-테트라진-8-카르복스아미드, 3,4-디하이드로-3-메틸-4-옥소-
  • 엠앤비 39831
  • 글리오템
  • 테미졸

Undergo tumor resection surgery

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Event free survival (EFS)
기간: Up to 3 years

EFS time is calculated from time of randomization to Arms A or B to first episode of disease relapse or progression, second malignancy, or death, or until last contact if no event has occurred.

Up to 3 years

2차 결과 측정

결과 측정
측정값 설명
기간
End of Induction (EOI) response rate
기간: From randomization to end of extended Induction, up to 12 months

The response rate will be calculated among all evaluable patients at end of Induction. Responders are defined as patients who achieve a >= partial response per the revised 2017 International Neuroblastoma Response Criteria (INRC)

From randomization to end of extended Induction, up to 12 months
Overall survival (OS)
기간: Up to 3 years

OS time is calculated from time of randomization to Arms A or B until death, or until last contact if patient is alive.

Up to 3 years
Incidence of adverse events
기간: Up to 2 years

The proportion of patients with at least one grade 3 or higher non-hematologic toxicity or grade 4 or higher hematologic toxicity during protocol therapy, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0, will be reported.

Up to 2 years
GD2 expression
기간: Up to 12 months

Dinutuximab binding to pre-therapy patient tumor samples will be measured and categorized as high or low.

Up to 12 months

기타 결과 측정

결과 측정
측정값 설명
기간
Association between tumor and host factors and outcomes
기간: Up to 10 years

A series of univariate and multivariate Cox proportional hazards (for EFS and OS) and logistic regression (for responders vs. non-responders) models will be fit for patients in Arms A and B to evaluate the relationship between tumor and host factors (including tumor ALK and other somatic mutations, copy-number aberrations, gene fusions, gene expression, and pathogenic germline variants) and chemo-immunotherapy during Induction with outcome.

Up to 10 years
Circulating biomarkers and markers of minimal residual disease
기간: Up to 10 years

Will be assessed by comparing the proportion of patients with detectable vs. non-detectable tumor markers (including circulating tumor deoxyribonucleic acid, circulating free DNA, circulating tumor cells, and immune function profiling) between Arms A and B during and after induction and post-consolidation therapy using chi-squared tests at each individual time point, and Cochran's Q across time points to determine if there is a consistent difference in proportions between arms across time. In addition, the tumor markers will be analyzed as continuous variables using longitudinal data analysis methodology such as mixed effects models or generalized estimating equations as appropriate.

Up to 10 years
Patterns of failure
기간: Up to 10 years

The impact of early or late chemoimmunotherapy during Induction on the probability of the involvement of a specific disease site at first relapse will be evaluated using Fisher's exact test.

Up to 10 years
Effect of telomere maintenance mechanisms
기간: Up to 10 years

A series of univariate and multivariate Cox proportional hazards (for EFS and OS) and logistic regression (for responders vs. non-responders) models will be fit for patients in arms A and B to evaluate the relationship between telomere maintenance mechanism and chemoimmunotherapy during Induction with outcome. Patients will be classified into 3 groups by telomere maintenance mechanism (TMM) based on messenger ribonucleic acid expression of TERT and analysis of telomeric DNA C-circles: telomerase (TERT) positive, alternative of lengthening of telomeres (ALT) positive, or no identified TMM.

Up to 10 years
Functional and quality of life outcomes
기간: At serial time points during Induction, Extended Induction, Post-Consolidation, and at the end of therapy

Will descriptively summarize and compare the total Memorial Symptom Assessment Scale scores, total sub-domain scores, and individual symptom scores between patients randomized to receive dinutuximab during Induction (Arm B) to those of patients randomized to standard Induction (Arm A).

At serial time points during Induction, Extended Induction, Post-Consolidation, and at the end of therapy
Adequacy of diagnostic biopsy specimens
기간: At time of tissue collection

Will be evaluated by descriptively comparing the successful delineation of histologic classification, MYCN amplification status, and ALK status via the traditional method of obtaining tissue for diagnosis, open surgical biopsy, versus the less invasive percutaneous core needle biopsy.

At time of tissue collection
Associations between family-reported adverse social determinants of health and both clinical outcomes and biology
기간: Up to 10 years

Kaplan-Meier curves of EFS and OS will be generated and used to calculate 3-year EFS and OS estimates. Associations between social determinants of health (SDOH) and survival outcomes and time to receipt of dinutuximab will be evaluated with univariate and multivariate Cox proportional hazard models. Log-binomial regression will be used to estimate risk ratios and 95% CI for the occurrence of dinutuximab consent to randomization and therapy receipt by SDOH exposure. Effect modification of outcomes as a function of poverty, stratified by race/ethnicity, will be explored.

Up to 10 years
Develop and validate deep learning predictors of Induction response (imaging objective)
기간: At diagnosis, EOI, during Extended Induction, and end of Extended Induction

Scans will be given as input to a convolutional neural network trained to predict EOI response.

At diagnosis, EOI, during Extended Induction, and end of Extended Induction
Compare institutional versus central determination of overall response, individual response components, and PEIR and GEIR determination (imaging objective)
기간: Up to 10 years

Will be assessed by calculating the percentage of patients receiving the same EOI institutional and centrally reviewed determination of overall response, individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease), and PEIR and GEIR. In addition, Cohen's kappa will be calculated to evaluate the concordance in each of these response measures.

Up to 10 years
Incidence of late toxicities
기간: Up to 10 years

Will be addressed by calculating the proportion of treated patients with each late effect, including but not limited to impaired organ function, neuropsychiatric toxicity, and secondary malignancy. A 95% confidence interval will be placed on each proportion.

Up to 10 years
Reduced dose radiotherapy to the primary site clinical target volume (CTV) in patients with complete response of the primary site at EOI results in comparable local control relative to historical cohorts
기간: Up to 10 years

The cumulative incidence of local progression (CILP) in patients with complete response of the primary site at EOI and GEIR on this study will be compared to the CILP rate of 11.2±1.8% observed on ANBL0532 using Gray's test.

Up to 10 years
Post-transplant complications
기간: Up to 100 days post-transplant

Will be evaluated by calculating the incidence of endothelial injury complications and non-relapse mortality within 100 days of transplant, transplant-associated thrombotic microangiopathy (TA-TMA), severe TA-TMA, and sinusoidal obstruction syndrome (SOS) on Arms A and B and comparing between arms with a chi-squared test. The impact of TA-TMA occurrence on the timing or exclusion of subsequent therapy and interventions utilized to treat the TA-TMA, and associations with outcomes (EFS and OS) will be assessed.

Up to 100 days post-transplant
Associations between end of induction (EOI) response and individual response components
기간: Up to 10 years

Log-rank tests will be used to explore the association between EOI response (using both the revised INRC and GEIR/PEIR classification) and individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease) with outcome (EFS and OS).

Up to 10 years
Changes in image-defined risk factors (IDRF)
기간: Up to 10 years

The proportion of patients in the analytic cohort for whom each particular IDRF and also the presence of any IDRF is absent prior to surgical resection will be computed. McNemar's test for paired observations will be applied to determine whether there is a difference in the proportion of each IDRF and any IDRF present before and after initial therapy, and conditional logistic regression will be used to compare between treatment arms A and B. The IDRF status after initial therapy and whether there has been a change from diagnosis will be associated with surgical outcome (complete vs. incomplete resection, presence or absence of surgical complications) using chi-squared tests, and compared between treatment arms A and B with the Cochran-Mantel-Haenszel test. The association of IDRF status with presence or absence of local failure after primary tumor resection will also be evaluated using a chi-squared test, and compared between treatment arms A and B with the Cochran-Mantel-Haenszel.

Up to 10 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Sara M Federico, Children's Oncology Group

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 4월 19일

기본 완료 (추정된)

2029년 12월 31일

연구 완료 (추정된)

2029년 12월 31일

연구 등록 날짜

최초 제출

2023년 12월 13일

QC 기준을 충족하는 최초 제출

2023년 12월 13일

처음 게시됨 (실제)

2023년 12월 15일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 30일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 29일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

추가 관련 MeSH 약관

기타 연구 ID 번호

  • NCI-2023-08530
  • U10CA180886 (미국 NIH 보조금/계약)
  • NCI-2023-08530 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
  • ANBL2131 (기타 식별자: CTEP)
  • ANBL2131 (기타 식별자: Children's Oncology Group)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

"NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page."

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .